Dana-Farber/Brigham and Women's Cancer Center.
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9. doi: 10.6004/jnccn.2012.0128.
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström's Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.
这些 NCCN 指南解读重点介绍了 Waldenström 巨球蛋白血症/淋巴浆细胞淋巴瘤管理方面的重要更新/变化。其中包括将含有新型药物的方案作为一线和挽救治疗选择，纳入第六届 Waldenström 巨球蛋白血症国际研讨会更新的反应类别和标准摘要，以及在相关讨论中纳入周围神经病变管理部分。
